Tavolimab

N/A

Report date: 2024/07/05 20:00:49

Base Information

Drug NameTavolimab
Drug Alias NameTavolixizumabMEDI-0562
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor receptor superfamily member 4 agonists
TargetsTumor necrosis factor receptor superfamily member 4
Therapy Area/IndicationsSolid tumoursFallopian Tube NeoplasmsHead and Neck Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsNorway +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMedimmune
China Registration ClassN/A

Develop Information

Active CompaniesMedimmune LlcNordic Society Of Gynaecological Oncology
Inactive CompaniesN/A
Active IndicationsFallopian Tube NeoplasmsHead and Neck NeoplasmsOvarian Neoplasms +[9] 
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A